Pulmonary sarcomatoid carcinoma: University of Cincinnati experience

Nagla Abdel Karim; James Schuster; Ihab Eldessouki; Ola Gaber; Tariq Namad; Jiang Wang; Changchun Xie; John C. Morris

doi:10.18632/oncotarget.23468

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Pulmonary sarcomatoid carcinoma: University of Cincinnati experience

Nagla Abdel Karim, James Schuster, Ihab Eldessouki, Ola Gaber _, Tariq Namad, Jiang Wang, Changchun Xie and John C. Morris

PDF | HTML | How to cite

Oncotarget. 2018; 9:4102-4108. https://doi.org/10.18632/oncotarget.23468

Metrics: PDF 1919 views | HTML 3454 views | ?

Abstract

Nagla Abdel Karim1, James Schuster2, Ihab Eldessouki1, Ola Gaber1, Tariq Namad3, Jiang Wang4, Changchun Xie5 and John C. Morris1

1Vontz Center for Molecular Studies, University of Cincinnati, Cincinnati, OH 45219, USA

2University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA

3Military Hospital of Mohammed V, Department of Medical Oncology, Quartier Irfane, Rabat 10080, Morocco

4UC Health University Hospital, Department of Pathology and Laboratory Medicine, Cincinnati, OH 45219, USA

5Division of Biostatistics and Bioinformatics, Department of Environmental Health, Cincinnati, OH 45267, USA

Correspondence to:

Ola Gaber, email: [email protected]

Keywords: chemotherapy; lung cancer; non-small cell lung cancer; sarcomatoid

Received: October 10, 2017 Accepted: November 19, 2017 Published: December 18, 2017

ABSTRACT

Objectives: To review the outcomes of treatment in patients with pulmonary sarcomatoid carcinoma (PSC) treated at the University of Cincinnati Medical Center (UCMC).

Results: There was no significant difference in survival of patients treated with chemotherapy alone (median, 256 days) compared to patients not undergoing treatment (median, 205.5 days). Patients who underwent surgery and adjuvant chemotherapy showed a trend in improvement of survival (median, 457.6 days). Patients requiring only surgery had the longest OS of 713.5 days.

Conclusions: Systemic chemotherapy alone did not improve survival in patients with PSC. Surgery provides the greatest overall survival benefit and adjuvant chemotherapy may also improve survival.

Methods: From 2000 to 2014, twenty-five patients with pathologically confirmed PSC were treated at UCMC. The outcomes were retrospectively analyzed by treatment with overall survival (OS) as the endpoint.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23468

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Pulmonary sarcomatoid carcinoma: University of Cincinnati experience

Abstract